Genetics Study of In-stent Restenosis

• Conditions: Coronary Artery Disease

• Registration Number: NCT01670396
• Lead Sponsor: Shanghai Zhongshan Hospital

Brief Summary

The investigators hypothesized that genetic variants of G protein influence the development of restenosis and clinical outcome of patients receiving drug-eluting stents (DES).

Detailed Description

Although drug-eluting stents (DES) have reduced restenosis rates compared with bare-metal stents, the restenosis rate is still high in the high-risk group. G protein plays important roles in the signal transduction leading to vascular smooth muscle proliferation. The initial and subsequent studies suggest that the T allele of C825T polymorphism is associated with enhanced transmembrane signaling via Gi proteins.

Study Timeline

• Study Start: 2012-03
• Status Verified: 2012-08
• Primary Completion: 2012-08
• Study First Submitted: 2012-08-15
• Study First Submitted QC: 2012-08-19
• Last Update Submitted: 2012-08-19
• Study First Posted: 2012-08-22
• Last Update Posted: 2012-08-22
• Study Completion: 2012-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Patients who underwent follow-up angiography. All the patients must had been implanted with DES during the last two years.

Exclusion Criteria

• For the non-ISR group, the patients underwent follow-up angiography less than 6 months away from stent implanting.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
In-stent restenosis	6-24months after stent implanting

Secondary Outcome Measures

Name	Time	Method
target lesion revascularization (TLR)	6-24months after stent implanting
re-myocardial infarction	6-24months after stent implating

Trial Locations

Locations (1)

Zhongshan Hospital; 🇨🇳 Shanghai, China